Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

Benzinga Newsdesk www.benzinga.com Neutral 61.1%

Neg 0% Neu 61.1% Pos 0%

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $24.